Hormone cycling: a new hope for advanced prostate cancer?
NCT ID NCT07142551
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new way to treat metastatic prostate cancer that has stopped responding to standard hormone therapy. Researchers will give men high doses of testosterone followed by a drug called darolutamide, repeating this cycle to see if it keeps the cancer from growing longer. The trial involves 60 men and aims to check safety, cancer progression, and quality of life.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
RECRUITINGBaltimore, Maryland, 21205, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Chemo combo vs. radioactive drug: which tames aggressive prostate cancer?
- Can a new pill outsmart resistant prostate cancer?
- Can a radioactive 'Smart Bomb' outsmart advanced prostate cancer?
- Can an immune booster make hormone therapy work better against prostate cancer?
- Can a pill outsmart Tumors' defenses?
- Can targeted radiation tame advanced prostate cancer? a registry aims to find out